Supportive oligonucleotide SOT therapy in Philadelphia
Supportive oligonucleotide (SOT) therapy, a cutting-edge approach in the field of gene silencing, has garnered significant attention for its potential in treating various disorders. This innovative therapeutic strategy involves the use of short sequences of nucleotides, known as oligonucleotides, to modulate gene expression and address underlying genetic abnormalities.
Single infusions of SOT starts at $2000
SOT Therapy presents a tailored approach to combat cancer, viruses, and pathogens like Lyme Disease. This therapy targets a specific gene associated with the malignant cell or pathogen, disrupting crucial processes that support their survival or growth. In the course of treatment, the patient’s blood is examined, and a customized oligonucleotide sequence is crafted to impede the cells’ survival or growth. RGCC SOTs are exclusively accessible to RGCC Network doctors.
How Supportive Oligonucleotide (SOT) Therapy Works:
SOT Therapy, categorized as an gene silencing or antisense therapy, is meticulously crafted to influence a specific RNA sequence in viruses, bacteria, pathogens, or malignant cells. Antisense oligonucleotides (ASOs) or small interfering RNA (siRNA) can be designed to target specific pathogenic or malignant RNA and inhibit replication. This slowdown gives the immune system a chance to recover and better handle the infection as well.
Various mechanisms are employed in Supportive oligonucleotide (SOT) therapy for gene silencing. Antisense oligonucleotides, for instance, are designed to bind to specific RNA molecules, blocking their normal function and preventing the synthesis of disease-related proteins. Another approach involves the use of small interfering RNA (siRNA), which triggers the degradation of specific mRNA molecules, thereby inhibiting the translation of genetic information into proteins.
One of the key advantages of Supportive Oligonucleotide therapy lies in its specificity. Unlike traditional treatments that may affect multiple genes or pathways, this approach allows for a highly targeted intervention. This precision minimizes the risk of unintended side effects and enhances the therapeutic potential of the treatment.
SOT for EBV
In the context of EBV, SOT Therapy aims to harness the power of oligonucleotides to selectively target and silence specific viral genes or elements essential for the virus’s replication and survival. This approach leverages the principles of gene silencing to interfere with the expression of viral genes, ultimately inhibiting the virus’s ability to infect and replicate within host cells.
SOT for Lyme
Supportive Oligonucleotide Therapy (SOT) for Lyme disease holds promise as a targeted approach to combat the bacterial infection caused by Borrelia burgdorferi. This innovative therapy utilizes oligonucleotides to selectively interfere with essential bacterial genes, aiming to disrupt the pathogen’s survival and replication within the host. Antisense oligonucleotides (ASOs) or small interfering RNA (siRNA) can be designed to target specific bacterial RNA, hindering the synthesis of crucial proteins required for the bacterium’s viability.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680246/
https://projectlyme.org/Supportive-oligonucleotide-therapy-sot-for-lyme/
SOT for Cancer
Supportive Oligonucleotide Therapy (SOT) for cancer represents a groundbreaking approach in the realm of precision medicine. This therapeutic strategy involves using oligonucleotides, such as antisense oligonucleotides (ASOs) or small interfering RNA (siRNA), to selectively target and silence specific genes associated with cancer. By disrupting the expression of key oncogenes or signaling pathways, SOT Therapy aims to inhibit tumor growth and progression. The specificity of this approach minimizes collateral damage to healthy cells, potentially reducing side effects compared to traditional cancer treatments. Ongoing research and clinical trials are exploring the feasibility of SOT Therapy for various cancer types, with a focus on optimizing delivery methods and ensuring the safety and efficacy of this innovative therapy in the complex landscape of cancer treatment.
Frequently Asked Questions about the O-Shot
Once the blood has been tested and verified for a specific pathogen or cancer, the SOT injection is processed and made at the RGCC laboratories. Once delivered to our clinic, the SOT is given via infusion over 1-3 hours. Patients should do no other therapies 2 weeks before and 1 month after SOT to allow for scavenging and targeting of specific cells. Typically, 1-3 infusions are needed, depending on the case. Total effectiveness is reached between 6-9 months.
Single infusions of SOT start at $2000, depending on the case.
Reserve Your Appointment Today
For more information on SOT Therapy in Philadelphia, or to reserve an appointment, contact Meeting Point Health today!
